Consistently with this concept, we found that HSD11B1 expression was also associated with poor prognosis in stomach adenocarcinoma, and it has been shown that HSD11B2 is also expressed in the gastrointestinal tract.26 In addition, HSD11B1 overexpression or gain mutations were associated with poor clinical outcome in patients with gastrointestinal stromal tumors.11 This evidence concerns the gene HSD11B1 and gastric adenocarcinoma.